Satellos Bioscience Inc. (NASDAQ:MSLE – Free Report) – HC Wainwright boosted their FY2030 earnings per share (EPS) estimates for Satellos Bioscience in a research note issued on Monday, May 18th. HC Wainwright analyst A. He now anticipates that the company will earn $0.35 per share for the year, up from their prior forecast of $0.34. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Satellos Bioscience’s current full-year earnings is ($2.29) per share.
Other analysts have also issued research reports about the company. Zacks Research upgraded Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Satellos Bioscience in a report on Monday, May 11th. Leerink Partners assumed coverage on Satellos Bioscience in a report on Monday, April 6th. They set an “outperform” rating and a $20.00 target price for the company. Guggenheim assumed coverage on Satellos Bioscience in a research report on Tuesday, April 28th. They set a “buy” rating and a $23.00 price target on the stock. Finally, Cantor Fitzgerald assumed coverage on Satellos Bioscience in a research report on Wednesday, March 11th. They set an “overweight” rating on the stock. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.00.
Satellos Bioscience Stock Performance
Satellos Bioscience stock opened at $7.15 on Tuesday. The business’s fifty day moving average is $7.41. The stock has a market capitalization of $148.93 million, a price-to-earnings ratio of -4.47 and a beta of 1.60. Satellos Bioscience has a twelve month low of $4.53 and a twelve month high of $13.39.
Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02).
Satellos Bioscience Company Profile
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.
Recommended Stories
- Five stocks we like better than Satellos Bioscience
- 3 Dividend Stocks With Insiders Buying in 2026
- Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade?
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
Receive News & Ratings for Satellos Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satellos Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
